Vyepti
(Eptinezumab)ApprovedMonoclonal antibody
LundbeckEptinezumab is used to prevent migraine headaches in adults who have frequent migraines. It is given as an injection every three months to reduce how often migraines occur.[2] Vyepti is currently approved and in use across 9 indications[4].[1]
Vyepti is one of 159 monoclonal antibody programs targeting Migraine Without Aura. It is currently in Approved.
9
Indications
24
Total Trials
9
Active Trials
158
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Vyepti
LundbeckApproved
Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Savella
AbbViePreclinical
Bayer Aspirin
BayerPreclinical
Adempas
BayerPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Viagra
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine12 trials
Show 9 more trials
Headache4 trials
Cluster headache2 trials
Adult1 trial
3 more indications
Migraine Without Aura1 trial
Unspecified2 trials
Facilitators and Barriers to Eptinezumab Administration in Thailand
Recruiting·—··NCT07035197·30 enrolled
Regulatory
FDA Approval Timeline[5]
Feb 21, 2020
VYEPTI
BLA BLA761119
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Vyepti drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Eptinezumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]